The estimated Net Worth of Tal Zvi Zaks is at least $13.9 Million dollars as of 15 June 2024. Tal Zaks owns over 21,108 units of Moderna Inc stock worth over $3,907,121 and over the last 8 years he sold MRNA stock worth over $5,205,790. In addition, he makes $4,832,430 as Chief Medical Officer at Moderna Inc.
Tal has made over 74 trades of the Moderna Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 21,108 units of MRNA stock worth $1,678,297 on 15 June 2024.
The largest trade he's ever made was exercising 125,044 units of Moderna Inc stock on 26 May 2020 worth over $1,611,817. On average, Tal trades about 18,277 units every 19 days since 2016. As of 15 June 2024 he still owns at least 49,140 units of Moderna Inc stock.
You can see the complete history of Tal Zaks stock trades at the bottom of the page.
Dr. Tal Zaks M.D. Ph.D. serves as Chief Medical Officer of the Company. Prior to joining the Company, Dr. Zaks served in senior development positions at Sanofi (NYSE: SNY) from 2010 to 2015, including Senior Vice President and Head of Global Oncology. From July 2008 to May 2010, he served as Vice President of Clinical Research, Oncology at Cephalon. Prior to this, Dr. Zaks spent four years at GlaxoSmithKline (NYSE: GSK) as Director, Clinical Development and Translational Medicine and three years at the National Cancer Institute as a Postdoctoral Fellow. He is currently an Associate Professor of Medicine at the University of Pennsylvania and serves on the board of directors of Adaptimmune Therapeutics plc (Nasdaq: ADAP). Dr. Zaks received his M.D. and Ph.D. from the Ben Gurion University in Israel and conducted post-doctoral research at the U.S. National Institutes of Health. He completed his clinical training in intern
As the Chief Medical Officer of Moderna Inc, the total compensation of Tal Zaks at Moderna Inc is $4,832,430. There are 2 executives at Moderna Inc getting paid more, with Stephane Bancel having the highest compensation of $8,948,210.
Tal Zaks is 54, he's been the Chief Medical Officer of Moderna Inc since 2015. There are 10 older and 8 younger executives at Moderna Inc. The oldest executive at Moderna Inc is Elizabeth Tallett, 71, who is the Director.
Tal's mailing address filed with the SEC is C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, L3, 6944020.
Over the last 6 years, insiders at Moderna Inc have traded over $2,713,086,305 worth of Moderna Inc stock and bought 52,631 units worth $999,989 . The most active insiders traders include Noubar Afeyan, David M. Rubenstein, and Stephane Bancel. On average, Moderna Inc executives and independent directors trade stock every 2 days with the average trade being worth of $2,841,687. The most recent stock trade was executed by Shannon Thyme Klinger on 6 September 2024, trading 1,139 units of MRNA stock currently worth $90,562.
moderna is pioneering messenger rna therapeutics™, an entirely new in vivo drug modality that produces human proteins or antibodies inside patient cells, which are in turn active intracellularly or secreted. this breakthrough platform addresses currently undruggable targets, and offers a superior alternative to existing drug modalities for a wide range of disease conditions. moderna has developed a broad intellectual property estate including more than 200 patent applications with more than 10,000 claims ranging from novel nucleotide chemistries to specific drug compositions. the company plans to develop and commercialize its innovative mrna drugs—initially for rare diseases and oncology—while partnering drug candidates in other therapeutics areas in order to rapidly deliver this innovation to patients. based in cambridge, massachusetts, moderna is privately held and was founded in 2010 by flagship venturelabs in association with leading scientists from boston children’s hospital a
Moderna Inc executives and other stock owners filed with the SEC include: